Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

How Old Are You? Your Body Might Disagree With That Answer


Dr. Nathan Price, left, and John C. Earls.

Dr. Nathan Price, left, and John C. Earls.

“While most people agree that they know (wellness) when they see it, holistic quantification of wellness has proven to be elusive. This study is one step toward making that quantification more rigorous and understandable by the general population.” — John C. Earls, lead author

Is age really just a number? Traditionally, our chronological age — the number of birthdays we’ve celebrated — has also broadly served as a marker of health, disease and mortality.

But what if our chronological age isn’t the best way to make those assessments?

Researchers at the Institute for Systems Biology (ISB) harnessed deep molecular and physiological information to determine an individual’s biological age, which they found was reflective of overall health compared to chronological age. The findings were published in the Journals of Gerontology: Series A, in a special issue on Healthy Aging, sponsored by AARP.

“A major interest of the Hood-Price Lab for Systems Biomedicine at ISB is understanding ‘wellness’,” said John C. Earls, lead author of the study. “Wellness is a term that is used a lot. While most people agree that they know it when they see it, holistic quantification of wellness has proven to be elusive. This study is one step toward making that quantification more rigorous and understandable by the general population.

“People don’t understand what it means that their biochemistry puts them in a certain region of high-dimensional space enriched for a negative phenotype,” Earls said. “That is not the sort of information a person can internalize and act on. On the other hand, telling a person that they have the biochemistry of a 50-year-old when they are only 40 is something that makes sense to people. Then being able to tell them that most of this deviation is coming from sugar levels or inflammation, gives them a path to improve their wellness.”

Earls, et al, applied an algorithm to longitudinal data collected from more than 3,500 people participating in a consumer wellness program. The personalized data consisted of genetic, clinical laboratory, metabolomic and proteomic assays.

Researchers found that biological age estimates from deep phenotyping changed in expected directions for both positive and negative health conditions — “healthy” behaviors (such as participation in a wellness program) were associated with delta age (biological age minus chronological age) becoming lower over the time periods tested, while “unhealthy” conditions (such as self-reported diseases) were associated with increased biological age compared with chronological age.

These findings suggest that biological age can be modified, and that lower biological age compared to chronological age could, in general, be a sign of healthy aging. “We believe biological age represents one general and interpretable metric for wellness that may aid in monitoring aging over time,” said Nathan Price, PhD, the corresponding author of the study and co-leader of the Hood-Price Lab.

“Importantly, not all measurements that change with age are bad,” Price said. “Some of them can be protective or important responses to damage over time. However, many of these are associated with decreased health and increased likelihood of developing disease, and so having a comprehensive view of biological aging across multiple systems can provide much actionable information about the current state of health and how it may be improved.”

The study sampled men and women who varied by age and health status and who participated in Arivale (now closed), which was a consumer data-intensive “scientific wellness” program. The wellness program also included lifestyle coaching on exercise, nutrition, stress management, and sleep — all tailored to participants’ health goals, specific genetic markers, and clinical metrics.

The study used data collected over three years ending in July of 2018 from those who gave research consent. The Arivale data were de-identified following consent from program participants.

This study builds on other important ISB findings, notably that the alpha diversity of an individual’s gut microbiome can be accurately predicted by examining metabolites in the blood, and that combining personal, dense, dynamic data (PD3) clouds with tailored behavioral coaching can optimize wellness, and that the PD3 clouds can identify early transitions into disease states and facilitate the reversal of some disease states back to wellness.

“We are thankful to everyone in the Arivale program who wanted to provide their (de-identified) data for this research,” said Lee Hood, MD, PhD, who co-founded ISB in 2000. “These individuals are absolutely critical to understanding health and wellness, and transforming the health care system into the modern era. Arivale has made striking advances in the formulation of 21st Century Medicine.”

ABOUT ISB

Institute for Systems Biology is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including brain health, cancer, sepsis and aging, as well as many chronic and infectious diseases. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence St. Joseph Health, one of the largest not-for-profit health care systems in the United States.

Share article on social media or email:

Syngulon and Eppen sign a MOU for the development of a new generation of feed probiotics leveraging bacteriocins as a natural alternative to antibiotics


Eppen and Syngulon join forces to develop a World’s leading new generation of feed probiotics leveraging bacteriocins as a natural and safe alternative to antibiotics

During the Belgian Economic Mission to the People’s Republic of China, Eppen and Syngulon have signed in Beijing on November 18 a MOU (Memorandum of Understanding) for the development of a new generation of feed probiotics leveraging bacteriocins as a natural alternative to antibiotics to enhance animal nutrition and health. Eppen is a Chinese leader in nutrition and health solutions with the world’s leading production capacities and a global sales network. Syngulon is a synthetic biology startup developing original technologies using bacteriocins, discovered in Belgium in 1925 by André Gratia, that are produced by a wide variety of microorganisms. Syngulon has developed the world’s largest collection of bacteriocins.

In a context of fast-growing protein demand worldwide, the feed industry has been relying on antibiotics used as growth promoters (AGP) to boost animal growth. Such AGP are, however, associated with risks of antibiotics resistance, thus posing health safety issues for animals and indirectly for humans. While these AGP are therefore to be banned in the feed industry in China in 2020, the industry is looking for some relevant alternatives.

Eppen and Syngulon have decided to join forces to develop a World’s leading new generation of feed probiotics leveraging bacteriocins as a natural and safe alternative to antibiotics to enhance both animal nutrition and health in a cost-effective and sustainable way therefore meeting the growing demand for safe, healthy and affordable food.

Share article on social media or email:

Diagenode to Offer Single-Cell ATAC-Seq Services Featuring Bio-Rad’s Droplet Digital Technology


“Bio-Rad is pleased to partner with Diagenode, a key player in the epigenetics market.”

Diagenode, Inc., a leading global provider of solutions for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s Droplet Digital technology, to help advance epigenomics research.

Diagenode’s scATAC-Seq Services leverage the combined capabilities of Bio-Rad’s Droplet Digital technology and Diagenode’s epigenetics expertise to help researchers gain a greater understanding of the epigenome, the multitude of chemical compounds and proteins that give instructions to the genome. The scATAC-Seq Services utilize Bio Rad’s ddSEQ Single-Cell Isolator to encapsulate thousands of cell nuclei or whole cells into nanoliter-sized droplets and offer robust precision and quantification of data.

scATAC-Seq solutions enable the genome-wide study of accessible chromatin that represents regulatory regions at the single-cell level. In contrast to standard bulk ATAC-Seq, scATAC-Seq provides a way for thousands of cells to be assessed in parallel to better parse heterogeneous populations.

“We are excited to offer scientists the combination of Diagenode’s epigenetic service excellence and Bio-Rad’s industry-leading scATAC-Seq technology,” said Joe Bertelsen, Business Unit Manager at Diagenode. “This collaboration demonstrates our continued commitment to enabling advances in epigenomics research.”

“Bio-Rad is pleased to partner with Diagenode, a key player in the epigenetics market,” said Kris Simonyi, Global Marketing Manager at Bio-Rad’s Digital Biology Group. “By working together to combine our expertise, we look forward to accelerating epigenetics and gene regulation research at the single-cell level.”

To learn more about Diagenode’s Single-Cell ATAC-Seq Services, please visit: https://www.diagenode.com/p/single-cell-atac-seq-service

BIO-RAD, DDSEQ, and DROPLET DIGITAL SEQ are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit http://www.bio-rad.com.

About Diagenode, Inc.

Diagenode is a leading provider of complete solutions for epigenetic research and epigenomics services. The company has developed a comprehensive approach to gain new insights into epigenetic studies, offering innovative shearing and automation instruments, reagent kits, and high-quality antibodies to streamline DNA methylation, noncoding RNA-seq, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique full automation system, a Reduced Representation Bisulfite Sequencing (RRBS) Kit providing eight times more coverage than standard technologies, ChIPmentation and ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.

Bio-Rad Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Share article on social media or email:

$1.4M Grant to Investigate New Treatment for High LDL Cholesterol


Dayami Lopez, Ph.D. conducting research in an NCCU research lab.

“Heart disease causes about a quarter of all deaths each year,” Lopez said. “It occurs because of a combination of genetic mutations and environmental factors, including lack of exercise and too much fat in the diet.”

North Carolina Central University Associate Professor Dayami Lopez, Ph.D., was awarded a $1.48 million grant from the National Institute for General Medical Sciences to study new means of treating high cholesterol and preventing heart disease.

The four-year grant will advance Lopez’s research into regulation of low-density lipoproteins, also known as LDL cholesterol, considered a major risk factor in heart disease.

“Heart disease causes about a quarter of all deaths each year,” Lopez said. “It occurs because of a combination of genetic mutations and environmental factors, including lack of exercise and too much fat in the diet.”

Statins, a class of medicines known to block cholesterol production in the liver, are widely used to treat patients with high LDL. However, not all patients respond well to statins. Some have serious side effects, and others, including those with a genetic marker for high cholesterol, fail to improve.

A secondary treatment type that controls cholesterol by regulating Proprotein convertase subtilisin/kexin type 9 series, or PCSK9 protein, has been in use since 2015. But this treatment is expensive, costing hundreds of dollars a month, and often not covered by health insurance, Lopez said.

Lopez is now working to develop a third type of treatment that controls PCSK9 using the Alpha 1 antitrypsin protein, a method expected to be lower cost and more affecting in people with genetically based high cholesterol.

“Data from a previous study has given us, for the first time, concrete evidence that Alpha 1 antitrypsin will interact with PCSK9,” Lopez said. “Now we are looking into the mechanics of that. We will be using cell lines from three different ethnic groups: Caucasian, Asian and African American.”

Because of genetic differences, some ethnic groups, including African Americans, are at greater risk for having high cholesterol.

The NIH funding will provide $370,000 per year over four years to assist in development of the potential new treatment.

Along with her research, Lopez is the founder of the startup NIFP Technologies LLC, incorporated in January 2018 to market diagnostic tests and novel therapeutics stemming from the collaborative work of Lopez and Associate Professor of Biology Sean Kimbro, Ph.D. Other company partners include NCCU biosciences researcher Quantil Melendez, Ph.D., who serves as chief executive officer, and BRITE science researchers Catherine Wooten, Ph.D., and Sumaira Ahmed, Ph.D.

    

Share article on social media or email:

Fluidigm, Pacific Biosciences, and Thermo Fisher Receive Top Honors at Life Science Industry Awards


2019 Life Science Industry Awards logo

With their in-depth understanding of customer needs, each of these innovative companies establishes differentiation and improves their competitiveness in every phase of their products’ life cycle — from the actual design and manufacture of the product to its pricing, delivery, and post-sale support.

BioInformatics Inc., part of Science and Medicine Group, the leading research and advisory firm serving the life science tools market, today announced the winners of the Life Science Industry Awards for the most innovative new products in 2019.

Here are the 2019 winners of the Life Science Industry Awards – Innovation:

Most Innovative New Product – Cell Biology

  • Fluidigm (Gold Award) for its Maxpar Direct Immune Profiling System
  • Tecan (Silver Award) for its Spark Cyto plate reader with real-time image cytometry
  • Agilent Technologies (Bronze Award) for its xCELLigence RTCA eSight


Most Innovative New Product – Genomics

  • Pacific Biosciences (Gold Award) for its Sequel II System
  • Agilent Technologies (Silver Award) for its Magnis NGS Prep System
  • Thermo Fisher Scientific (Bronze Award) for its QuantStudio 6 and 7 Pro Real-Time PCR Systems


Most Innovative New Product – Protein Analysis

  • Thermo Fisher Scientific (Gold Award) for its Orbitrap Exploris 480 Mass Spectrometer
  • Gyros Protein Technologies (Silver Award) for its PurePep Chorus
  • Bruker (Bronze Award) for its timsTOF fleX


“With their in-depth understanding of customer needs, each of these innovative companies establishes differentiation and improves their competitiveness in every phase of their products’ life cycle — from the actual design and manufacture of the product to its pricing, delivery, and post-sale support,” said Craig Overpeck, chief executive officer of Science and Medicine Group, parent company of BioInformatics. “Through our countless surveys, interviews, focus groups, and hundreds of reports, we’re proud to have played a role in our clients’ successes by helping them see their markets and themselves through the eyes of their customers.”

Since 2002, the Life Science Industry Awards have recognized manufacturers of the “tools of science” that help advance biological research and drug discovery. Beginning in 2019, the Life Science Industry Awards have expanded to include three new categories to recognize the most innovative new products released this year. The editors of Instrument Business Outlook and the scientists who comprise BioInformatics’ market insights team selected the winners.

For more information, please visit http://www.LifeScienceIndustryAwards.com.

ABOUT BIOINFORMATICS INC.

BioInformatics Inc., now part of Science and Medicine Group, is the premier research and advisory firm serving the life science and analytical instrument industries. By leveraging our expert network of more than 50,000 life scientists, the company has supported more than 500 companies in creating insights that lead to better business decisions. Together with IMV, Kalorama Information, and SDi, Science and Medicine group offers clients unmatched insights and reach in the life science, analytical instruments, clinical laboratory, medical imaging, and dental markets.

Share article on social media or email:

Trivedi Global, Inc. Announces that Jagdish Singh Reaches International No. 1 Amazon Best Seller


Jagdish Singh

Jagdish Singh

The powerful impact of Jagdish Singh’s gifts and ability to harness and transmit the universal intelligent energy to any part of the globe has been scientifically validated, documented, and published in international peer-reviewed scientific journals.

“Effect of the Biofield Energy Treated Test Formulation on Tissue Specific Biomarkers in Various Human Cells” by Jagdish Singh has been named No. 1 International Best Seller and Hot New Release on Amazon in many categories including Occupational and Industrial Medicine, Nursing Issues: Trends and Roles, Microbiology, Cell Biology, Digestive Organs, and One-Hour Short Reads for Science and Math in the USA and Canada.

The aim of Singh’s research was to evaluate the effect of the Consciousness Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain in various cell-based assays.

About Biofield Energy Treatments

The National Center of Complementary and Integrative Health (NCCIH) has recognized and accepted Biofield Energy Healing Treatments as a complementary and alternative medicine (CAM) health care approach in addition to other therapies, medicines, and practices. CAM therapies have been practiced worldwide with reported clinical benefits in different health disease profiles. Human Biofield Energy has subtle energy that has the capacity to work in an effective manner. This energy can be harnessed and transmitted by the gifted into living and non-living things via the process of a Biofield Energy Healing Treatment or Therapy.

About Jagdish Singh

Jagdish Singh is a successful IT leader with over 25 years of experience in the industry. Singh has always held a keen interest in spirituality and natural healing. In 2011, he had the great fortune of meeting Guruji Mahendra Trivedi, founder of Trivedi Global, Inc., and the Trivedi Effect®. Guruji Trivedi helped Singh develop and uncover his gifts. The powerful impact of his gifts and ability to harness and transmit the universal intelligent energy to any part of the globe has been scientifically validated, documented, and published in international peer-reviewed scientific journals. The energy creates desirable impacts on the recipient, living or nonliving, and was duly measured through preclinical scientific research using both cell-based and mice models. The results suggest significant benefits and improvements in overall health, well-being, quality of life, skin quality, anti-aging, Vitamin D3 absorption, bone health, and more.

http://www.singhjagdish.com/

About the Trivedi Effect® & Guruji Mahendra Trivedi

The Trivedi Effect® is an evidence-based phenomenon in which an individual can harness inherently intelligent energy from nature and transmit it to living organisms and non-living materials, anywhere in the world through thought intention, to significantly enhance potency and beneficially alter their characteristics and behaviors through transformation at the atomic, molecular, and cellular levels.

Guruji Mahendra Kumar Trivedi, Founder of the Trivedi Effect®, is on a mission to usher in a new era that integrates science, spirituality, and consciousness to vastly improve the human condition and benefit humanity on a global scale. To date, more than 250,000 people worldwide have benefited from the Trivedi Effect®. His organization, Trivedi Global, Inc., is collaborating with globally renowned product research and development organizations to bring to market proprietary products and therapies in the areas of nutraceuticals, pharmaceuticals, and more.

Alice Branton, CEO of Trivedi Global, Inc., has spoken on the impact of the Trivedi Effect® at the Entrepreneurship Club of the Harvard Business School, Nasdaq, Microsoft, and Coca-Cola. She has also appeared on more than 35 network television news shows including ABC, NBC, FOX, CW and more.

Dahryn Trivedi is a prodigious spiritual leader, young entrepreneur and inspiring speaker. Along with Guruji Mahendra Trivedi she devotes her time to expand and promote awareness about the power and potential of the Trivedi Effect®. She has shared her message at NASDAQ and has been featured on ABC, NBC, Fox, CW media in the United States.

Gopal Nayak is one the youngest enlightened spiritual gurus for the new generation in India. He is a pioneer in Biofield Energy Science. Nayak raises awareness about the potential impact of the Trivedi Effect for the beneficial transformation of all living organisms and non-living materials. Nayak is highly sought after by business leaders, politicians and celebrities throughout India and abroad. Nayak has transformed the lives of thousands of individuals from around the world, especially in the USA, Canada and Europe.

The Trivedi Effect® has been tested, measured, and validated in more than 6,000 scientific experiments globally, by world-renowned scientists and research institutes using the rigor of internationally accepted models of scientific research with the most sophisticated technologies available. Challenging the known frontiers of science, this research has resulted in over 500 publications in major international peer-reviewed scientific journals with more than 6,500 citations.

These publications are available in over 2,300 universities internationally including the prestigious Ivy League Universities, as well as the National Institutes of Health (NIH).

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause actual results in future periods to differ materially from stated results. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, and orientations regarding the future. Often, but not always, forward-looking statements can be identified by words such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, “appear”, or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved.

Media Contacts

Jagdish Singh

234-738-1628

jagdish@singhjagdish.com

Alice Branton,

Chief Executive Officer

Trivedi Global, Inc.

(702) 907-8864

pr@trivedieffect.com

Microturbines Growing in Power and Value


The increase in unit production is attributable to the new, very small microturbines that are currently coming to market.

Defense and aerospace market intelligence firm Forecast International is projecting worldwide production of about 8,500 microturbine electrical power generation units from 2019-2028. The value of this production is $728 million in 2019 dollars. This is a significant increase over 2017’s projection of 3,821 units worth $569 million.

Reference to 2017 is important, as that was a pivotal year in the microturbine market. “The increase in unit production is attributable to the new, very small microturbines that are currently coming to market,” said Carter Palmer, microturbine analyst for FI.

Microturbines have generally grown in power output over the years, and that generally still holds. When microturbines started to become a significant market factor in 1999, the average unit on sale had a power output of about 35 kW. Ten years later, this had increased to approximately 100 kW and is now approaching 150 kW. “There is no indication that the trend of power increases is slowing,” Carter said.

There is also a trend developing in Europe of utilizing turbine technology in very small applications. There was a time when microturbines were too powerful for a private residence, but times are slowly changing. MTT’s EnerTwin produces 3.2 kW of electricity and 15.6 kW of thermal power, which puts the machine in a prime position to be utilized in smaller buildings. These new turbines change the forecast dramatically. From 2017’s projection to the outlook in the current analysis, unit production sees major growth.

These new small machines (e.g., MTT’s and Bladon’s products) might change the landscape somewhat, but previous trends still hold true: microturbines are becoming more powerful, more fuel options are becoming available, and Capstone is still the market leader in terms of value. The company is expected to garner $540.7 million in value of production during the forecast period, far more than the other competitors combined.

Today, microturbines are primarily used for remote power applications in the oil and gas (O&G) industry and for cooling, heating, and power (CHP) and combined CHP (CCHP) applications in the commercial, industrial, and residential high-rise markets. The success of Bladon’s 12-kW machine would add power in remote locations to the list. An increasing energy demand-supply gap, a rise in the adoption of low-emission power generation sources, and the need to generate power cost-efficiently are among the factors that will hold microturbines’ place in the market globally.

About Forecast International

Forecast International, Inc. is a leading provider of Market Intelligence and Consulting in the areas of aerospace, defense, power systems and military electronics. Based in Newtown, Conn., USA, the company specializes in long-range industry forecasts and market assessments used by strategic planners, marketing professionals, military organizations, and governments worldwide. Forecast International also maintains a high posture of situational awareness and geopolitical analysis.

Share article on social media or email:

Diagenode to Offer Single-Cell ATAC-Seq Services Featuring Bio-Rad’s Droplet Digital PCR Technology


“Bio-Rad is pleased to partner with Diagenode, a key player in the epigenetics market.”

Diagenode, Inc., a leading global provider of solutions for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s Droplet Digital PCR technology, to help advance epigenomics research.

Diagenode’s scATAC-Seq Services leverage the combined capabilities of Bio-Rad’s Droplet Digital PCR (ddPCR) technology and Diagenode’s epigenetics expertise to help researchers gain a greater understanding of the epigenome, the multitude of chemical compounds and proteins that give instructions to the genome. The scATAC-Seq Services utilize Bio Rad’s ddSEQ Single-Cell Isolator to encapsulate thousands of cell nuclei or whole cells into nanoliter-sized droplets and offer robust precision and quantification of data.

scATAC-Seq solutions enable the genome-wide study of accessible chromatin that represents regulatory regions at the single-cell level. In contrast to standard bulk ATAC-Seq, scATAC-Seq provides a way for thousands of cells to be assessed in parallel to better parse heterogeneous populations.

“We are excited to offer scientists the combination of Diagenode’s epigenetic service excellence and Bio-Rad’s industry-leading scATAC-Seq technology,” said Joe Bertelsen, Business Unit Manager at Diagenode. “This collaboration demonstrates our continued commitment to enabling advances in epigenomics research.”

“Bio-Rad is pleased to partner with Diagenode, a key player in the epigenetics market,” said Kris Simonyi, Global Marketing Manager at Bio-Rad’s Digital Biology Group. “By working together to combine our expertise, we look forward to accelerating epigenetics and gene regulation research at the single-cell level.”

To learn more about Diagenode’s Single-Cell ATAC-Seq Services, please visit: https://www.diagenode.com/p/single-cell-atac-seq-service

BIO-RAD, DDPCR, and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit http://www.bio-rad.com.

About Diagenode, Inc.

Diagenode is a leading provider of complete solutions for epigenetic research and epigenomics services. The company has developed a comprehensive approach to gain new insights into epigenetic studies, offering innovative shearing and automation instruments, reagent kits, and high-quality antibodies to streamline DNA methylation, noncoding RNA-seq, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique full automation system, a Reduced Representation Bisulfite Sequencing (RRBS) Kit providing eight times more coverage than standard technologies, ChIPmentation and ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.

Bio-Rad Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Share article on social media or email:

WPI Engineers Creating Miniaturized, Wireless Oxygen Sensor for Sick Infants


Professor Ulkuhan Guler shows off an early prototype of the miniaturized, wearable device that will one day monitor infants’ blood oxygen levels.

Professor Ulkuhan Guler shows off an early prototype of the miniaturized, wearable device that will one day monitor infants’ blood oxygen levels.

Researchers at Worcester Polytechnic Institute (WPI) are developing a sensor the size of a Band-Aid that will measure a baby’s blood oxygen levels, a vital indication of the lungs’ effectiveness and whether the baby’s tissue is receiving adequate oxygen supply. Unlike current systems used in hospitals, this miniaturized wearable device will be flexible and stretchable, wireless, inexpensive, and mobile—possibly allowing the child to leave the hospital and be monitored remotely.

Ulkuhan Guler, assistant professor of electrical and computer engineering and director of WPI’s Integrated Circuits and Systems Lab, is leading the project focused on enabling sick, hospitalized babies to be untethered from wired sensors, so they can more easily and frequently be examined, held, and even allowed to go home. Guler and her team have developed a miniature oxygen monitor for babies, which measures blood gases diffusing through the skin and reports the data wirelessly.

“Extended stays in the hospital are costly and can be a strain on families,” said Guler. “And studies have shown that babies’ health improves when they are with their families. Our goal with this affordable, mobile device is to give doctors more flexibility in monitoring their patients both in the hospital and at home.”

Typically, measuring oxygen molecule levels transcutaneously involves using a system with an approximately 5-pound monitor plugged into an electrical outlet, and sensors that generally are wired to the monitor. Guler’s healthcare device will use wireless power transfer. It also will be connected to the Internet wirelessly so an alarm on a monitor in a doctor’s office or smartphone app would notify medical personnel and family members if the baby’s oxygen level begins to drop.

The device is designed to measure PO2, or the partial pressure of oxygen, which indicates the amount of oxygen dissolved in the blood—a more accurate indicator of respiratory health than a simple oxygen saturation measurement, which can be easily taken with a pulse oximetry device gently clamped on a finger. And measuring the PO2 level via a noninvasive device attached on the skin is as accurate as a blood test.

The wearable baby oxygen monitor also would be useful for adults, especially people with severe asthma and seniors with COPD, or Chronic Obstructive Pulmonary Disease, which is an incurable, progressive lung disease and the third leading cause of death in the United States, according to the Centers for Disease Control and Prevention. Guler will modify the wearable for adults, and create a related smartphone app, in another phase of her research.

Guler is collaborating with Pratap Rao, associate professor of mechanical engineering at WPI, and Lawrence Rhein, MD, chair of the department of pediatrics and an associate professor at the University of Massachusetts Medical School. Ian Costanzo and Devdip Sen, both graduate students in electrical and computer engineering at WPI, also are working with Guler to create a chip that will eventually act as the heart for the wearable device.

“The concept of the technology is that if we have more accessible data for a person of any age, we’ll be able to better take care of these patients,” said Rhein, who has been advising Guler on what’s needed in a hospital and home setting. “The idea of noninvasive, untethered, accessible data collection opens up a whole new world of care.”

The chip, designed to work inside the wearable oxygen monitor, activates the optical sensors, captures analogue signals from the sensor, handles power management, and contains required circuitry. Guler and the team have custom designed the individual circuits, such as signal capturing circuits and driver circuits for optical based read-out circuits. In the next phase of the research project, they plan to equip the chip with more circuitries to digitize the analogue signals, transmit the captured and digitized data, and create power from a wireless link. At that point, it will be a complete system on the chip.

In an interdepartmental collaboration, Guler and Rao are creating miniaturized thin and flexible sensors for the wearable healthcare devices so they will be comfortable and secure on the babies while they’re moving.

The team has written four papers (two more papers are in preparation about their research) focusing separately on miniaturizing devices, creating the prototype, oxygen measurement techniques, and building the chip. Three of the papers are under review. One, titled “A Prototype Towards a Transcutaneous Oxygen-Sensing Wearable,” was presented at the Biomedical Circuits and Systems Conference, or BioCAS 2019, in Nara, Japan in October.

About Worcester Polytechnic Institute

WPI, the global leader in project-based learning, is a distinctive, top-tier technological university founded in 1865 on the principle that students learn most effectively by applying the theory learned in the classroom to the practice of solving real-world problems. Recognized by the National Academy of Engineering with the 2016 Bernard M. Gordon Prize for Innovation in Engineering and Technology Education, WPI’s pioneering project-based curriculum engages undergraduates in solving important scientific, technological, and societal problems throughout their education and at more than 50 project centers around the world. WPI offers more than 50 bachelor’s, master’s, and doctoral degree programs across 14 academic departments in science, engineering, technology, business, the social sciences, and the humanities and arts. Its faculty and students pursue groundbreaking research to meet ongoing challenges in health and biotechnology; robotics and the internet of things; advanced materials and manufacturing; cyber, data, and security systems; learning science; and more. http://www.wpi.edu

Contact:

Colleen Bamford Wamback

Associate Director of Public Relations

Worcester Polytechnic Institute

Worcester, Massachusetts

508-831-6775 (office)

508-688-4858 (cell)

cbwamback@wpi.edu

7 Companies Nominated for a Life Science Industry Award for Innovation


LSIA 2019 logo

BioInformatics Inc., part of Science and Medicine Group, the leading research and advisory firm serving the life science tools market, today announced that 7 companies have been nominated for a Life Science Industry Award for launching one of the most innovative new products in 2019.

Since 2002, the Life Science Industry Awards have recognized manufacturers of the “tools of science” that help advance biological research and drug discovery. Traditionally, the Life Science Industry Awards have been a bi-annual event where thousands of life scientists nominate and vote for the best performing supplier in 10 distinct customer support, service and communications categories.

Beginning in 2019, the Life Science Industry Awards have expanded to include three new categories to recognize the most innovative new products released this year. The editors of Instrument Business Outlook and the scientists who comprise BioInformatics’ market insights team will select winners.

Here are the 2019 Nominees for the Life Science Industry Awards – Innovation:

Best New Product – Cell Biology

Agilent

  • • xCELLigence RTCA eSight

Fluidigm

  • • Maxpar Direct Immune Profiling System

Tecan

  • • Spark Cyto plate reader with real-time image cytometry

2019 Nominees: Best New Product – Genomics

Agilent Technologies

  • • Magnis NGS Prep System

Pacific Biosciences

Thermo Fisher Scientific

  • • QuantStudio 6 and 7 Pro Real-Time PCR Systems

2019 Nominees: Best New Product – Protein Analysis

Bruker

Gyros Protein Technologies

Thermo Scientific

  • • Orbitrap Exploris 480 Mass Spectrometer

The winners of the 2019 Life Science Industry Awards for Innovation will be announced via webinar on November 20th, 2019 at 2:00pm EST.

For more information please visit http://www.LifeScienceIndustryAwards.com; or you register for the announcement of winners here: https://attendee.gotowebinar.com/register/6175849463820728075

ABOUT BIOINFORMATICS INC.

BioInformatics Inc., now part of Science and Medicine Group is the premier research and advisory firm serving the life science and analytical instrument industries. By leveraging our expert network of more than 50,000 life scientists, the company has supported more than 500 companies in creating insights that lead to better business decisions. Together with IMV, Kalorama Information, and SDi, Science and Medicine group offers clients unmatched insights and reach in the life science, analytical instruments, clinical laboratory, medical imaging and dental markets.

Share article on social media or email: